Core Facility for Abeta Microdialysis Drug Discovery Platform

2007 to 2009

In collaboration with an anonymous funder, Cure Alzheimer’s Fund is supporting development of a facility to measure the concentration of Amyloid-beta in real time in the brain of living, behaving mouse models that develop features of AD. The model enables screening for drugs that lower Amyloid-beta directly in the brain in relatively high throughput.


Funding to Date

$278,238

Focus

Drug Discovery

Researchers

David Holtzman, M.D.